JP2019514393A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514393A5 JP2019514393A5 JP2018557312A JP2018557312A JP2019514393A5 JP 2019514393 A5 JP2019514393 A5 JP 2019514393A5 JP 2018557312 A JP2018557312 A JP 2018557312A JP 2018557312 A JP2018557312 A JP 2018557312A JP 2019514393 A5 JP2019514393 A5 JP 2019514393A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- nucleic acid
- acid molecule
- composition
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 121
- 238000000034 method Methods 0.000 claims description 85
- 102000039446 nucleic acids Human genes 0.000 claims description 67
- 108020004707 nucleic acids Proteins 0.000 claims description 67
- 150000007523 nucleic acids Chemical class 0.000 claims description 67
- 210000004027 cell Anatomy 0.000 claims description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
- 239000000556 agonist Substances 0.000 claims description 48
- 108020001507 fusion proteins Proteins 0.000 claims description 41
- 102000037865 fusion proteins Human genes 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 41
- 210000002865 immune cell Anatomy 0.000 claims description 40
- 239000013612 plasmid Substances 0.000 claims description 39
- 230000003248 secreting effect Effects 0.000 claims description 39
- 239000003623 enhancer Substances 0.000 claims description 30
- 208000035475 disorder Diseases 0.000 claims description 28
- 230000002163 immunogen Effects 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 26
- 230000000139 costimulatory effect Effects 0.000 claims description 24
- 108010040721 Flagellin Proteins 0.000 claims description 22
- 230000001580 bacterial effect Effects 0.000 claims description 22
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 18
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 18
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 18
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims description 18
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 18
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims description 18
- 230000030833 cell death Effects 0.000 claims description 18
- 108010002350 Interleukin-2 Proteins 0.000 claims description 16
- 102100032937 CD40 ligand Human genes 0.000 claims description 14
- 230000003463 hyperproliferative effect Effects 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 14
- 102000008579 Transposases Human genes 0.000 claims description 13
- 108010020764 Transposases Proteins 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- -1 CD86 Proteins 0.000 claims description 12
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 12
- 239000013603 viral vector Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 108010029697 CD40 Ligand Proteins 0.000 claims description 8
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 8
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 8
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 8
- 108010002586 Interleukin-7 Proteins 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000037361 pathway Effects 0.000 claims description 8
- 102100027206 CD2 antigen cytoplasmic tail-binding protein 2 Human genes 0.000 claims description 6
- 102100027207 CD27 antigen Human genes 0.000 claims description 6
- 101150013553 CD40 gene Proteins 0.000 claims description 6
- 102100025221 CD70 antigen Human genes 0.000 claims description 6
- 102100035793 CD83 antigen Human genes 0.000 claims description 6
- 101000914505 Homo sapiens CD2 antigen cytoplasmic tail-binding protein 2 Proteins 0.000 claims description 6
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 6
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 claims description 6
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 6
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 6
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims description 6
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 6
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 102100034980 ICOS ligand Human genes 0.000 claims description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 6
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 6
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 6
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 claims description 6
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims description 6
- 102000004473 OX40 Ligand Human genes 0.000 claims description 6
- 108010042215 OX40 Ligand Proteins 0.000 claims description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 6
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 6
- 210000000987 immune system Anatomy 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 238000003559 RNA-seq method Methods 0.000 claims description 4
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 210000001772 blood platelet Anatomy 0.000 claims description 4
- 239000002458 cell surface marker Substances 0.000 claims description 4
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 210000003714 granulocyte Anatomy 0.000 claims description 4
- 210000003630 histaminocyte Anatomy 0.000 claims description 4
- 230000005847 immunogenicity Effects 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 210000003593 megakaryocyte Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 102000040430 polynucleotide Human genes 0.000 claims description 4
- 108091033319 polynucleotide Proteins 0.000 claims description 4
- 239000002157 polynucleotide Substances 0.000 claims description 4
- 230000011664 signaling Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 238000007482 whole exome sequencing Methods 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 102000004452 Arginase Human genes 0.000 claims description 2
- 108700024123 Arginases Proteins 0.000 claims description 2
- 206010003571 Astrocytoma Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 101000840545 Bacillus thuringiensis L-isoleucine-4-hydroxylase Proteins 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 2
- 102100024263 CD160 antigen Human genes 0.000 claims description 2
- 102100038078 CD276 antigen Human genes 0.000 claims description 2
- 101710185679 CD276 antigen Proteins 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100031351 Galectin-9 Human genes 0.000 claims description 2
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims description 2
- 208000032320 Germ cell tumor of testis Diseases 0.000 claims description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 claims description 2
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 claims description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 2
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 2
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 claims description 2
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101001102797 Homo sapiens Transmembrane protein PVRIG Proteins 0.000 claims description 2
- 101000801254 Homo sapiens Tumor necrosis factor receptor superfamily member 16 Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 102000002698 KIR Receptors Human genes 0.000 claims description 2
- 108010043610 KIR Receptors Proteins 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 2
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 101150065403 NECTIN2 gene Proteins 0.000 claims description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 claims description 2
- 102100035488 Nectin-2 Human genes 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 101710114148 Phase 1 flagellin Proteins 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 101001037255 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Indoleamine 2,3-dioxygenase Proteins 0.000 claims description 2
- 241000607142 Salmonella Species 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 2
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100039630 Transmembrane protein PVRIG Human genes 0.000 claims description 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 229960005305 adenosine Drugs 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 102000045108 human EGFR Human genes 0.000 claims description 2
- 102000052073 human NGFR Human genes 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 210000003289 regulatory T cell Anatomy 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 claims description 2
- 210000004872 soft tissue Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000002918 testicular germ cell tumor Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022029582A JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662331906P | 2016-05-04 | 2016-05-04 | |
| US62/331,906 | 2016-05-04 | ||
| PCT/US2017/031171 WO2017192924A1 (en) | 2016-05-04 | 2017-05-04 | Cell-based neoantigen vaccines and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029582A Division JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514393A JP2019514393A (ja) | 2019-06-06 |
| JP2019514393A5 true JP2019514393A5 (enExample) | 2020-06-11 |
| JP7033549B2 JP7033549B2 (ja) | 2022-03-10 |
Family
ID=58739362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018557312A Active JP7033549B2 (ja) | 2016-05-04 | 2017-05-04 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
| JP2022029582A Pending JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022029582A Pending JP2022091750A (ja) | 2016-05-04 | 2022-02-28 | 細胞に基づくネオ抗原ワクチンおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11723962B2 (enExample) |
| EP (1) | EP3452082A1 (enExample) |
| JP (2) | JP7033549B2 (enExample) |
| CA (1) | CA3022267A1 (enExample) |
| WO (1) | WO2017192924A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11278570B2 (en) | 2016-12-16 | 2022-03-22 | B-Mogen Biotechnologies, Inc. | Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods |
| KR102523318B1 (ko) | 2016-12-16 | 2023-04-18 | 비-모젠 바이오테크놀로지스, 인크. | 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법 |
| EP3612632A2 (en) | 2017-04-18 | 2020-02-26 | Yale University | A platform for t lymphocyte genome engineering and in vivo high-throughput screening thereof |
| CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
| WO2019086711A1 (en) * | 2017-11-06 | 2019-05-09 | Ludwig Institute For Cancer Research Ltd | Method for expansion of lymphocytes |
| EP3706770A4 (en) * | 2017-11-07 | 2021-10-27 | Nektar Therapeutics | IMMUNOTHERAPEUTIC COMBINATION FOR THE TREATMENT OF CANCER |
| EP3743083A4 (en) * | 2018-01-23 | 2021-11-03 | Vanderbilt University | SELF-ANTIGEN SPECIFIC T-LYMPHOCYTES AS VACCINES TO INCREASE ENGINEERING AND STABILITY OF AUTOLOGOUS TRANSFER |
| WO2019173441A1 (en) * | 2018-03-06 | 2019-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of preparing populations of cells and retroviral reagents for adoptive cell immunotherapy |
| EP3781678A4 (en) * | 2018-04-18 | 2022-06-01 | Yale University | Compositions and methods for multiplexed tumor vaccination with endogenous gene activation |
| WO2020036646A2 (en) * | 2018-04-25 | 2020-02-20 | The Methodist Hospital System | Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy |
| TW202000906A (zh) * | 2018-05-23 | 2020-01-01 | 美商葛利史東腫瘤科技公司 | 免疫檢查點抑制劑共表現載體 |
| MX2020012649A (es) * | 2018-05-25 | 2021-07-02 | The Wistar Inst | Neoantígenos especificos de tumor y métodos de uso de estos. |
| EP3810764A2 (en) | 2018-06-21 | 2021-04-28 | B-Mogen Biotechnologies, Inc. | Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods |
| JP2021534752A (ja) | 2018-08-22 | 2021-12-16 | フレッド ハッチンソン キャンサー リサーチ センター | Ｋｒａｓ抗原またはｈｅｒ２抗原を標的とする免疫療法 |
| WO2020097530A2 (en) | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting mesothelin |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| CN113164578B (zh) * | 2019-01-03 | 2024-04-30 | 南京传奇生物科技有限公司 | 表达鞭毛蛋白多肽的经修饰的免疫细胞 |
| CN111454358A (zh) * | 2019-01-18 | 2020-07-28 | 四川科伦博泰生物医药股份有限公司 | 一种嵌合抗原受体及其应用 |
| GB2596461B (en) | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2021043804A1 (en) * | 2019-09-02 | 2021-03-11 | Institut Curie | Immunotherapy targeting tumor neoantigenic peptides |
| CN110804594B (zh) * | 2019-11-21 | 2020-11-20 | 启辰生生物科技(珠海)有限公司 | 工程化抗原递呈细胞及其在用于活化cd3+免疫细胞中的应用 |
| AU2021253641A1 (en) * | 2020-04-07 | 2022-10-27 | Evaxion Biotech A/S | Neoepitope immunotherapy with APC targeting unit |
| GB202006254D0 (en) * | 2020-04-28 | 2020-06-10 | Institute Of Cancer Res | Anti-cancer vaccines and related therapy |
| CN111690609B (zh) * | 2020-06-30 | 2022-04-05 | 深圳裕泰抗原科技有限公司 | 一种新生抗原免疫原性的测试方法 |
| CA3187258A1 (en) | 2020-08-06 | 2022-02-10 | Karin Jooss | Multiepitope vaccine cassettes |
| WO2022067038A1 (en) * | 2020-09-25 | 2022-03-31 | President And Fellows Of Harvard College | Immunotherapeutic virus for the treatment of cancer |
| AR124826A1 (es) * | 2021-02-08 | 2023-05-10 | Hutchinson Fred Cancer Res | Sistema y métodos para vincular la señalización de cd40 a la unión del antígeno |
| WO2023173116A1 (en) * | 2022-03-10 | 2023-09-14 | City Of Hope | Membrane-bound il-12 for cellular immunotherapy |
| WO2024118634A2 (en) * | 2022-11-28 | 2024-06-06 | The Trustees Of The University Of Pennsylvania | In vivo expansion of car t cells and delivery of car target antigen to tumors using mrna lipid nanoparticles |
| CN117338914B (zh) * | 2023-10-27 | 2024-09-06 | 中山市珈钰生物医药有限公司 | 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用 |
| WO2025101584A1 (en) * | 2023-11-06 | 2025-05-15 | Immunitybio, Inc. | Virally educated t cells |
| CN119823283B (zh) * | 2025-01-08 | 2025-08-26 | 国科明耀(山东)医学科技有限公司 | 一种il-12-cd137嵌合蛋白、一种功能增强型工程化nk细胞、其制备及应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US20020155093A1 (en) | 1997-02-18 | 2002-10-24 | Houghton Alan N. | Method for stimulation of an immune response to a differentiation antigen stimulated by an altered antigen |
| GB0224442D0 (en) | 2002-10-21 | 2002-11-27 | Molmed Spa | A delivery system |
| JP2006506072A (ja) * | 2002-11-12 | 2006-02-23 | デイッセロース，アルバート，ビー | アデノウイルスベクターワクチン |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| WO2005107381A2 (en) | 2004-05-07 | 2005-11-17 | Hans-Gustaf Ljunggren | Use of flagellin as an adjuvant for vaccine |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| EP1896570A2 (en) | 2005-05-10 | 2008-03-12 | Avaris AB | Cellular vaccine and use thereof |
| US20090324630A1 (en) | 2008-04-21 | 2009-12-31 | Jensen Michael C | Fusion multiviral chimeric antigen |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| JP6117515B2 (ja) | 2011-11-01 | 2017-04-19 | 国立大学法人名古屋大学 | 髄膜腫治療用医薬組成物 |
| KR20210108497A (ko) | 2013-02-26 | 2021-09-02 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| DK2981607T3 (da) | 2013-04-03 | 2020-11-16 | Memorial Sloan Kettering Cancer Center | Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller |
| CA2908434C (en) | 2013-04-07 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| AU2015231461B2 (en) | 2014-03-17 | 2021-09-09 | Tapimmune Inc. | Nucleic acid molecule vaccine compositions and uses thereof |
| CA2961179A1 (en) | 2014-09-14 | 2016-03-17 | Washington University | Personalized cancer vaccines and methods therefor |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| EA201790737A1 (ru) * | 2014-10-03 | 2017-08-31 | Новартис Аг | Комбинированная терапия |
| CN107106611B (zh) | 2014-10-27 | 2021-11-23 | 弗雷德哈钦森癌症研究中心 | 用于提高过继细胞免疫疗法效力的组合物和方法 |
| US20170268071A1 (en) | 2014-10-28 | 2017-09-21 | Thomas Jefferson University | COMPOSITIONS AND METHODS OF USING TRANSFER RNAS (tRNAs) |
| EP3294896A1 (en) | 2015-05-11 | 2018-03-21 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| EP4578480A3 (en) | 2015-10-01 | 2025-08-27 | QXMedical, LLC | Catheter structure with improved support |
| JP6923219B2 (ja) | 2015-11-03 | 2021-08-18 | ホーホシューレ ダルムシュタット | 選択的ｈｄａｃ８阻害剤およびこれらの使用 |
-
2017
- 2017-05-04 EP EP17724681.6A patent/EP3452082A1/en active Pending
- 2017-05-04 JP JP2018557312A patent/JP7033549B2/ja active Active
- 2017-05-04 WO PCT/US2017/031171 patent/WO2017192924A1/en not_active Ceased
- 2017-05-04 US US16/098,808 patent/US11723962B2/en active Active
- 2017-05-04 CA CA3022267A patent/CA3022267A1/en active Pending
-
2022
- 2022-02-28 JP JP2022029582A patent/JP2022091750A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514393A5 (enExample) | ||
| JP7340638B2 (ja) | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 | |
| US20200360431A1 (en) | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies | |
| CN113286811B (zh) | 改善过继性细胞疗法的效力和安全性 | |
| JP6588060B2 (ja) | 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用 | |
| US20200371091A1 (en) | Bcma-targeting chimeric antigen receptor, and uses thereof | |
| Inderberg et al. | T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reduces in vivo tumor growth | |
| CN114945382A (zh) | Cd19和cd22嵌合抗原受体及其用途 | |
| JP2022512968A (ja) | Ｔ細胞操作のための組成物および方法 | |
| CN110582488A (zh) | 具有增强功效的免疫效应细胞疗法 | |
| JP2024073656A (ja) | 生体内での存続性及び治療活性及びその増殖のためのｎｋｔ細胞サブセット | |
| JP2019514393A (ja) | 細胞に基づくネオ抗原ワクチンおよびその使用 | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| Shirjang et al. | Promising immunotherapy: Highlighting cytokine‐induced killer cells | |
| Yu et al. | CAR NK cell therapy for solid tumors: Potential and challenges | |
| Yang et al. | Mechanisms and clinical advancements of cell-based immunotherapies in nonsmall cell lung cancer: an integrated perspective | |
| TWI904120B (zh) | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 | |
| Pu et al. | Advances inadoptive cellular immunotherapy andtherapeutic breakthroughs inmultiple myeloma | |
| HK40090148A (zh) | 用於得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖 | |
| KR20250089551A (ko) | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 | |
| CN116322717A (zh) | 否决car-t细胞 | |
| Rapoport et al. | Adoptive T-Cell Transfer as a Clinical Antitumor Strategy for Hematologic Malignancies |